

Join us at a product theater sponsored by
Alnylam Pharmaceuticals!

A New Treatment Option: Discover AMVUTTRA™ (vutrisiran)

ABOUT THE PROGRAM*

Join our distinguished faculty as they discuss recognizing, diagnosing, and managing adult patients with polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. They will provide an overview of hATTR amyloidosis and review the clinical profile of AMVUTTRA, a new treatment for the polyneuropathy of hATTR amyloidosis in adults.

SPEAKERS

Amanda Peltier, MD, MS
Chief, Division of Neuromuscular Disorders
Professor, Department of Neurology and Medicine
Associate Vice Chair, Faculty Affairs
Vanderbilt University Medical Center
Nashville, TN

Brett Sperry, MD
Advanced Heart Failure and
Transplant Cardiologist
Saint Luke's Mid America Heart Institute
Kansas City, MO

PROGRAM DATE & TIME

Saturday, October 1, 2022
5:45 PM–6:45 PM ET

PROGRAM LOCATION

Prince George Exhibit Hall D&E
Industry Expert Theater 1
or
HFSA Virtual Learning Center

Indication

AMVUTTRA™ (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

For additional information about AMVUTTRA, please see the full [Prescribing Information](#) and visit www.amvuttrahcp.com.

This Industry Expert Theater presentation is not part of the scientific program as planned by the HFSA Program Committee. This event is neither sponsored by nor endorsed by HFSA.

This event does not qualify for continuing education credit.

*Intended for US Healthcare Professionals only.



AMVUTTRA and its associated logo are trademarks of Alnylam Pharmaceuticals, Inc.
© 2022 Alnylam Pharmaceuticals, Inc. All rights reserved. AMV-USA-00184

